Skip to content

Research on ceftazidime / avibactam precision treatment strategy for cro infected patients based on genomics data and machine learning algorithm

Research on ceftazidime / avibactam precision treatment strategy for cro infected patients based on genomics data and machine learning algorithm

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109804
Enrollment
Unknown
Registered
2025-09-25
Start date
2025-09-30
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carbapenem resistant Gram negative bacterial infections

Interventions

Real-time antimicrobial resistance gene-guided therapy group:none
Empirical therapy group:none

Sponsors

Wuxi People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old; 2. The diagnosis of CRO infection in the patient is clear; Complete records of the patient's basic information and course of illness; And receive CZA treatment for = 3 days; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. CRO colonization or contamination; 2. Allergic or intolerant to CZA; 3. Allergic or intolerant to CZA; 4. Patients with combined CRO bacteremia or sepsis; 5. In addition to infectious diseases, there are other diseases that affect the life of patients in a short term, such as pulmonary embolism, acute myocardial infarction, etc

Design outcomes

Primary

MeasureTime frame
30-day mortality rate;

Secondary

MeasureTime frame
14 -day clinical therapy failure rate;21 -day clinical therapy failure rate;21- day microbial clearance failure rate; 60 -day mortality rate;adverse drug reaction/event rate;

Countries

China

Contacts

Public ContactXiuhong Zhang

Wuxi People's Hospital

1091807068@qq.com+86 139 2111 4809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026